抗心律失常药物的使用在重新消灭和复发后的空白期,在帕洛克思动脉动中复发
Haoming You1, Sitong Li1, Xueyuan Guo1
1Department of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing, China.
Pacing and clinical electrophysiology : PACE
|April 2, 2025
概括
持续的抗心律失常药物治疗 (AAD) 经过重复切除对心房动 (PAF) 没有显著影响12个月内AF复发. 这一发现表明,AAD可能在重复废除后的空白期内没有关键作用.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
- 医学研究 医学研究
背景情况:
- 在3个月的空白期内,持续的抗失常药物 (AAD) 治疗对心房动 (AF) 预防的反复导管切除后的有效性尚不清楚.
- 对心房动 (PAF) 进行重复切除的目的是恢复鼻节律,但复发很常见.
研究的目的:
- 评估在空白期持续AAD治疗对PAF患者经历重复切除术的AF复发的影响.
- 为了确定AAD的使用是否会影响长期的结果.
主要方法:
- 来自中国-AF注册表的740名PAF患者 (2011-2022) 经历了重复切除术的回顾性分析.
- 在3个月的空白期内,患者被分为AAD和非AAD组.
- 考克斯的比例危险模型评估了AAD状态和12个月后AF复发之间的关联.
主要成果:
- 在740名患者中,有258名患者 (34.9%) 在去除后12个月经历了AF复发.
- 在空白期内使用AAD后,经过对混因子进行调整后,与AF复发没有显著的关联 (HR = 1.07;95% CI: 0.83-1.37;p = 0.599).
- 跨年龄,性别,BMI,左心脏直径和CHA2DS2-VASc得分的子组分析证实了这些发现.
结论:
- 在PAF重复切除后的空白期内持续AAD治疗与12个月后AF复发没有显著的相关性.
- 这些发现表明,AADs可能不会在早期的复发后消融阶段在预防AF复发中发挥关键作用.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
850
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
850
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
670
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
670
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
719
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
719
Disturbances in Heart Rhythm
737
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
737
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K
Cardiac Action Potential
663
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
663


